When two serious vascular conditions overlap, outcomes worsen dramatically — yet the therapeutic toolkit remains surprisingly thin. For the millions of adults living with both chronic kidney disease and peripheral artery disease simultaneously, a condition pairing that amplifies cardiovascular risk, accelerates functional decline, and drives disproportionate hospitalization rates, exercise training has barely been tested as a structured intervention. That evidence gap is the central concern of this narrative review.
The review, published in the Journal of Renal Nutrition, maps what is and is not known about exercise training in this dual-diagnosis population. In patients with either CKD or PAD in isolation, robust evidence — and corresponding clinical guidelines — already supports structured physical activity for improving cardiorespiratory fitness, lower-limb muscle strength, walking capacity, and health-related quality of life. But for patients carrying both diagnoses, the randomized controlled trial literature is effectively empty. A single observational cohort study hints that home-based walking programs may confer renal and cardiovascular benefits, but causality cannot be drawn from such data. The authors highlight an ongoing RCT, EXACT-CKD-PAD, as the field's best near-term opportunity to generate actionable evidence.
This review's importance lies less in what it reveals than in what it exposes. The CKD-PAD overlap is not a rare edge case — both conditions are highly prevalent in aging, diabetic, and hypertensive populations, meaning their co-occurrence is common. That exercise rehabilitation programs have been tested so infrequently in this group reflects a broader tendency in clinical trial design to exclude complex multimorbid patients, precisely the patients who might benefit most. The practical implication for practitioners is cautious: existing exercise protocols for either condition individually may offer a reasonable starting framework, but extrapolation carries risk given the unique hemodynamic and renal-clearance challenges of the combined phenotype. This is confirmatory of a known gap rather than a paradigm shift, and the field must await EXACT-CKD-PAD results before clinical guidance can meaningfully evolve.
